Tom is a patent litigator and partner within the litigation team, and joined EIP from a UK Magic Circle law firm in 2018.
During 10 years in private practice, Tom has experience of proceedings in the English High Court, Court of Appeal and Supreme Court. Tom acted in two of the most important patent cases in the last decade: for Warner-Lambert, a Pfizer group company, against Actavis and Mylan in relation to second medical use patent litigation in respect of its pain drug, Lyrica® (pregabalin), and for Unwired Planet and Conversant in proceedings against Huawei and ZTE on the issue of FRAND in the context of Standard- Essential Patents (SEPs) in the field of telecommunications.
Tom has extensive life sciences experience, having also represented Warner-Lambert against Sandoz in securing injunctive relief to prevent the launch of a full label generic version of Lyrica®, Biomet against Heraeus in trade secrets litigation concerning bone cements and acting for a leading pharmaceutical company on its global patent enforcement strategy in relation to one of its blockbuster drugs.
In the telecommunications sector, Tom acted for Optis in its successful enforcement of EP (UK) 2,229,744 against Apple. Tom currently acts for IP Bridge in SEP proceedings against Huawei. In his telecoms patent litigation practice, Tom has a particular interest and expertise in FRAND-related issues, including issues of jurisdiction and anti-suit relief.
Tom studied Modern Languages at the University of Oxford before starting his law career. He holds a Graduate Diploma in Law from BPP Law School, completed the Legal Practice Course at the College of Law, and has a Postgraduate Diploma in Intellectual Property Law from the University of Oxford.
Tom is well placed to advise clients on the new Unified Patent Court (UPC) - see further details at EIP Amar, our alliance created to support clients in any litigation before the UPC.